(Reuters) - Operating expenses were higher by 65 percent due to development costs of its drug candidates, the company said in a release.
Read more at Reuters.com Market News
The Longs and the Shorts of my trading on the JSE. My thoughts, actions and rambelings while trading. The thing I love best!
No comments:
Post a Comment